We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

84 hedge funds and large institutions have $207M invested in Adamas Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

10% less funds holding

Funds holding: 93 → 84 (-9)

27% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 26

34% less capital invested

Capital invested by funds: $316M → $207M (-$108M)

Holders
84
Holders Change
-9
Holders Change %
-9.68%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
19
Increased
38
Reduced
15
Closed
26
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
-$690K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$11.3M
2
AllianceBernstein
AllianceBernstein
Tennessee
+$11M
3
BWCA
Brenner West Capital Advisors
New York
+$9.15M
4
GGHC
Gilder Gagnon Howe & Co
New York
+$9.12M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.47M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$6.05M
2
Renaissance Technologies
Renaissance Technologies
New York
-$4.81M
3
EI
EAM Investors
California
-$4.01M
4
RFC
Russell Frank Company
Washington
-$2.4M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
76
Victory Capital Management
Texas
$11K +$994 +59 +8%
BlackRock
77
BlackRock
New York
$11K +$7.73K +459 +151%
QT
78
Quantbot Technologies
New York
$9K -$43.9K -2,604 -80%
Barclays
79
Barclays
United Kingdom
$3K -$926 -55 -19%
MA
80
MUFG Americas
New York
$2K +$2.1K +125 New
Geode Capital Management
81
Geode Capital Management
Massachusetts
$1.29K +$246K +14,633 +20%
MFS
82
MSI Financial Services
Massachusetts
$1K – – –
PMFA
83
Plante Moran Financial Advisors
Michigan
$1K +$792 +47 New
Renaissance Technologies
84
Renaissance Technologies
New York
– -$4.81M -169,900 Closed
EI
85
EAM Investors
California
– -$4.01M -141,448 Closed
RFC
86
Russell Frank Company
Washington
– -$2.4M -83,773 Closed
Ameriprise
87
Ameriprise
Minnesota
– -$1.84M -64,978 Closed
TC
88
TFS Capital
Pennsylvania
– -$1.72M -60,709 Closed
D.E. Shaw & Co
89
D.E. Shaw & Co
New York
– -$976K -34,474 Closed
Acadian Asset Management
90
Acadian Asset Management
Massachusetts
– -$850K -30,034 Closed
GC
91
Globeflex Capital
California
– -$612K -21,598 Closed
Marshall Wace
92
Marshall Wace
United Kingdom
– -$605K -21,348 Closed
Two Sigma Investments
93
Two Sigma Investments
New York
– -$563K -19,876 Closed
HCM
94
Highbridge Capital Management
New York
– -$464K -16,375 Closed
Simplex Trading
95
Simplex Trading
Illinois
– -$432K -15,281 Closed
Connor, Clark & Lunn Investment Management (CC&L)
96
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$385K -13,600 Closed
Asset Management One
97
Asset Management One
Japan
– -$326K -11,494 Closed
EMG
98
Ellington Management Group
Connecticut
– -$323K -11,417 Closed
Goldman Sachs
99
Goldman Sachs
New York
– -$304K -10,749 Closed
SCA
100
Secor Capital Advisors
New York
– -$294K -10,369 Closed
1 2 3
4
5

ADMS Hedge Fund Activity: Q1 2016 in Review

84 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2016, worth a combined $207M — down 34% from $316M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ADMS and 19 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 38 added.

The largest buyer was Great Point Partners, adding an estimated $11.3M. The largest seller was Millennium Management, cutting an estimated $6.05M.

  • 84 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2016, down from 93 in Q4 2015.
  • Funds reported $207M of Adamas Pharmaceuticals stock for Q1 2016, down 34% quarter-over-quarter.
  • 19 funds opened new Adamas Pharmaceuticals positions in Q1 2016 and 26 closed out, a net change of -7 holders.
  • The largest Adamas Pharmaceuticals buyer in Q1 2016 was Great Point Partners, an estimated $11.3M added.
  • The largest Adamas Pharmaceuticals seller in Q1 2016 was Millennium Management, an estimated $6.05M sold.

Based on aggregated 13F filings for Q1 2016.